Fundamental Pharmacotherapy for Severe Congestive Heart Failure
|
Accession number;05A0562673
|
| Title;Fundamental Pharmacotherapy for Severe Congestive Heart Failure |
| Author;
SASAKI SAE
(Kitasato Univ., Sch. of Med.)
IZUMI TOORU
(Kitasato Univ., Sch. of Med.)
|
Journal Title;Japanese Journal of Intensive Care Medicine
|
Journal Code:Z0581B
|
ISSN:0389-1194
|
|
VOL.29;NO.4;PAGE.293-299(2005)
|
| Figure&Table&Reference;FIG.4, TBL.1, REF.15 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;The clinical characteristics and prognosis of patients with congestive heart failure (CHF) have been described by a number of previous studies. Importantly, as our population ages, the incidence of chronic heart failure and its mortality rate will continue to increase. The management of CHF is a very important issue in clinical therapeutics, as CHF is the terminal stage of various cardiac disorders, including ischemic heart disease, hypertension, cardiomyopathy, and valvular disease. Recent large-scale clinical trials have provided credible evidence that angiotensin-converting enzyme inhibitors and beta-blockers can prolong the survival in with chronic heart failure. Recent experimental studies and clinical trials have revealed that the modulation of either systemic or regional (cardiovascular) rennin-angiotensin systems (RAS) is one of the potential targets to prevent the progression of heart failure. Either ACE inhibitor, angiotensin-II receptor blocker or aldosterone antagonist differently block RAS. Recently, a number of clinical trials showed that beta-blockers reduce mortality and morbidity in patients with heart failure. Possible mechanisms for this effect of beta-blockers induces protection from catecholamine myocyte toxicity, upregulation of beta-adrenergic signaling, attenuation of apoptosis, antiarrhythmic effect. Many clinical trials told us that each of them improves heart failure and might promise the better prognosis. (author abst.) |
|
|
|
Related Articles;
|
|
